Immutep Limited: Lapse Of Unlisted Options And Remaining Securities Update.pdf

44ldnwnjdzk9pb.pdf
Preview of Immutep Limited: Lapse of Unlisted Options and Remaining Securities Update
🔗 Source: asx.com.au
📊 Size: 226 KB
👤 Author: IMM
⬇️ Downloads: 24

Summary

Immutep Limited, a global biotechnology company focused on LAG-3 immunotherapeutic products for cancer and autoimmune disease, announced the lapse of 37,144,524 unlisted options (ASX Code: IMMAL) with an exercise price of $0.235 and an expiry date of 4 August 2020.

Remaining Options:
- 79,311 options at $0.568, expiring on 30 October 2020
- 102,628 options at $0.398, expiring on 7 March 2021
- 847,600 options at $0.248, expiring on 4 August 2025

Company Highlights:
- Lead product candidate: eftilagimod alpha (efti or IMP321), a soluble LAG-3 protein for metastatic breast cancer and other solid tumors.
- Clinical trials: AIPAC (NCT02614833), TACTI-002 (NCT03625323), INSIGHT-004 (NCT03252938), and TACTI-mel (NCT02676869).
- Additional LAG-3 products in development by partners.
- Agonist of LAG-3 (IMP761) for autoimmune disease.

Contact Information:
- Australian Investors/Media: Catherine Strong, Citadel-MAGNUS (+61 (0)406 759 268; [email protected])
- U.S. Media: Tim McCarthy, LifeSci Advisors (+1 (212) 915.2564; [email protected])

Description

Immutep Limited advises that 37,144,524 unlisted options over fully paid ordinary shares have lapsed.
Total remaining securities under ASX Code IMMAL are 79,311 + 102,628 + 847,600 options.
Immutep is a biotechnology company developing LAG-3 related immunotherapeutic products.

Technical Information

  • File Format: PDF
  • File Size: 226 KB
  • Pages: 1
  • Language: EN
  • Author: IMM
  • Total Downloads: 24
  • Last Updated: 7 days ago

Document Overview

This PDF document about Immutep Limited: Lapse of Unlisted Options and Remaining Securities Update provides comprehensive information and guidance. Whether you're a beginner or advanced user, this resource offers valuable insights into Immutep Limited: Lapse of Unlisted Options and Remaining Securities Update.

Related Topics

If you're interested in Immutep Limited: Lapse of Unlisted Options and Remaining Securities Update, you might also want to explore:

Download Immutep Limited: Lapse of Unlisted Options and Remaining Securities Update eBooks for free and learn more about Immutep Limited: Lapse of Unlisted Options and Remaining Securities Update. These books contain exercises and tutorials to improve your practical skills, at all levels!

Not satisfied with this document? We have related documents to Immutep Limited: Lapse of Unlisted Options and Remaining Securities Update, try searching with similar keywords: Immutep Limited: Lapse of Unlisted Options and Remaining Securities Update, Securities Issuance and Quotation Procedures for Immutep Limited, Immutep Limited Annual Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 for the Fiscal Year Ended June 30, 2019, D J Molles The Remaining Book 4 The Remaining Frac, Immutep Limited: LAG-3 Therapeutics Update - EGM Presentation (26 July 2021), Immutep Limited Business Update Webcast Slides, Immutep Limited 2021 Annual General Meeting Dates and Virtual Access Details, Immutep Limited: 1-for-11.8 Entitlement Offer Details and Instructions

You can download PDF versions of the user's guide, manuals and ebooks about Immutep Limited: Lapse of Unlisted Options and Remaining Securities Update, you can also find and download for free A free online manual (notices) with beginner and intermediate, Downloads Documentation, You can download PDF files (or DOC and PPT) about Immutep Limited: Lapse of Unlisted Options and Remaining Securities Update for free, but please respect copyrighted ebooks.